Cresco Labs is trading 5.24% down now at $0.78 after August 24–25 coverage highlighted sweeping consumer class-action and RICO allegations involving the company.
- The allegations claim cannabis products were marketed for therapeutic purposes without FDA approval; they remain unproven.
- An insurer’s lawsuit seeks to avoid defending or indemnifying Cresco in related class actions, increasing uncertainty around potential legal and insurance costs.